Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 30, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-30), Lexicon Pharmaceuticals's share price is $1.54. Lexicon Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.73. Hence, Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Lexicon Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 14.10. The lowest was 1.82. And the median was 5.09.

LXRX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.83
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Lexicon Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.21. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.73.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.20% per year.

During the past 13 years, Lexicon Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 32.00% per year. The lowest was -84.30% per year. And the median was 10.15% per year.

Lexicon Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Lexicon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

4.26

Lexicon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Lexicon Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.54	/	-0.729
	=

Lexicon Pharmaceuticals's Share Price of today is $1.54.
Lexicon Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.73.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Lexicon Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381

Website

https://www.lexpharma.com

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Executives

Philippe Amouyal	director	C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats	director, officer: President and CEO	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner	officer: SVP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade	officer: EVP, Gen. Counsel	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott	officer: VP, Human Resources	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a.	director, 10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc	director, 10 percent owner	750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth	officer: VP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub	officer: SVP, Regulatory & QA	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander	officer: VP, Finance and Accounting	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz	officer: SVP, Chief Medical Officer	58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer	officer: VP, Finance & Acctg	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381